

May 28, 2025

To

Listing Department,

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza,

Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

Company Code No. AUROPHARMA

To

The Corporate Relations Department

BSE LIMITED

Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001

Company Code No. 524804

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is to inform you that Curateq Biologics Private Limited, a wholly owned subsidiary of the Company, has incorporated a new wholly owned subsidiary in the Netherlands by the name of **CuraTeQ Biologics B.V.**

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as 'Annexure A'.

This is for your information and records.

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

Enclosures: Annexure A

AUROBINDO PHARMA LIMITED

(CIN: L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.



Annexure · A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

a) Name of the target entity, details in brief such as size, turnover etc.;	Name: CuraTeQ Biologics B.V., Netherlands
	Turnover: Not applicable as the company was incorporated on May 28, 2025.
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length";	CuraTeQ Biologics B.V., is incorporated as a wholly owned subsidiary of Curateq Biologics Private Limited, India, a wholly owned subsidiary of the Company and therefore is a related party of the Company. Promoters and promoter group of the Company are not interested in the transaction
c) Industry to which the business of the target entity being acquired belongs;	Biopharma Products industry
d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The object of incorporation of this wholly owned subsidiary is to expand the Biopharma Products business in Europe.
e) Brief details of any governmental or regulatory approvals required for the acquisition.	No governmental or regulatory approvals required.
f) Indicative time period for completion of the acquisition.	Not applicable
g) Nature of consideration - whether cash consideration or share swap or any other form and details of the same;	100% subscription to the share capital in cash.
h) Cost of acquisition and / or the price at which the shares are acquired; New Subsidiary was incorporated.	Initial subscription to the share capital of EURO 10,000 divided into 10000 shares with a nominal value of EURO 1.00 each.
i) Percentage of shareholding / control acquired and lor number of shares acquired;	100%
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	This is a newly incorporated Company and therefore the history of the last 3 years turnover is not available. Date of Incorporation is May 28, 2025.

AUROBINDO PHARMA LIMITED

(CIN: L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.